Molecular factors associated with regression of liver fibrosis of alcoholic etiology
- 作者: Kiseleva Y.1, Zharikov Y.1, Maslennikov R.1, Pavlov C.1, Nikolenko V.1,2
-
隶属关系:
- Sechenov First Moscow State Medical University (Sechenov University)
- Lomonosov Moscow State University
- 期: 卷 93, 编号 2 (2021)
- 页面: 204-208
- 栏目: Reviews
- URL: https://journals.rcsi.science/0040-3660/article/view/64764
- DOI: https://doi.org/10.26442/00403660.2021.02.200617
- ID: 64764
如何引用文章
全文:
详细
Liver fibrosis develops as a result of chronic liver damage of various etiologies, is characterized by excessive synthesis of connective tissue by activated stellate liver cells. The toxic effect of alcohol is one of the most significant and common etiological factors worldwide. Stellate cell activation results from the interaction of multiple molecular fibrogenic pathways triggered by intracellular and extracellular, hepatic and extrahepatic stimuli. Data analysis showed that knowledge about these abnormal pathways and biomolecular processes may further contribute to the improvement of approaches to assessment of disease prognosis and treatment of alcoholic liver disease.
作者简介
Ya. Kiseleva
Sechenov First Moscow State Medical University (Sechenov University)
Email: dr_zharikov@mail.ru
ORCID iD: 0000-0002-0009-9245
студентка Международной школы «Медицина будущего» ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
俄罗斯联邦, MoscowYu. Zharikov
Sechenov First Moscow State Medical University (Sechenov University)
编辑信件的主要联系方式.
Email: dr_zharikov@mail.ru
ORCID iD: 0000-0001-9636-3807
к.м.н., доц. каф. анатомии Института клинической медицины ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
俄罗斯联邦, MoscowR. Maslennikov
Sechenov First Moscow State Medical University (Sechenov University)
Email: dr_zharikov@mail.ru
ORCID iD: 0000-0001-7513-1636
к.м.н., ассистент каф. пропедевтики внутренних болезней Института клинической медицины ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
俄罗斯联邦, MoscowCh. Pavlov
Sechenov First Moscow State Medical University (Sechenov University)
Email: dr_zharikov@mail.ru
ORCID iD: 0000-0001-5031-9798
д.м.н., проф., зав. каф. терапии Института профессионального образования, рук. Центра доказательной медицины ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
俄罗斯联邦, MoscowV. Nikolenko
Sechenov First Moscow State Medical University (Sechenov University); Lomonosov Moscow State University
Email: dr_zharikov@mail.ru
ORCID iD: 0000-0001-9532-9957
д.м.н., проф., зав. каф. анатомии человека Института клинической медицины ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет), зав. каф. нормальной и топографической анатомии ФГБОУ ВО «МГУ им. М.В. Ломоносова»
俄罗斯联邦, Moscow; Moscow参考
- Sun M, Kisseleva T. Reversibility of liver fibrosis. Clin Res Hepatol Gastroenterol. 2015;39 Suppl. 1:S60-3. doi: 10.1016/j.clinre.2015.06.015
- Weiskirchen R, Tacke F. Liver Fibrosis: From Pathogenesis to Novel Therapies. Dig Dis. 2016;34(4):410-22. doi: 10.1159/000444556
- Zhang CY, Yuan WG, He P, et al. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic argets. World J Gastroenterol. 2016;22(48):10512-22. doi: 10.3748/wjg.v22.i48.10512
- Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015;64(5):830-41. doi: 10.1136/gutjnl-2014-30684
- Aydın MM, Akçalı KC. Liver fibrosis. Turk J Gastroenterol. 2018;29(1):14-21. doi: 10.5152/tjg.2018.17330
- Zoubek ME, Trautwein C, Strnad P. Reversal of liver fibrosis: From fiction to reality. Best Pract Res Clin Gastroenteroly. 2017;31(2):129-41. doi: 10.1016/j.bpg.2017.04.005
- Ramachandran P, Iredale JP, Fallowfield JA. Resolution of liver fibrosis: basic mechanisms and clinical relevance. Semin Liver Dis. 2015;35(2):119-31. doi: 10.1055/s-0035-1550057
- Moscoso CG, Steer CJ. “Let my liver rather heat with wine” – a review of hepatic fibrosis pathophysiology and emerging therapeutics. Hepat Med. 2019;11:109-29. doi: 10.2147/HMER.S213397
- Huang Y, Deng X, Liang J. Modulation of hepatic stellate cells and reversibility of hepatic fibrosis. Exp Cell Res. 2017;352(2):420-6. doi: 10.1016/j.yexcr.2017.02.038
- Feng M, Ding J, Wang M, et al. Kupffer-derived matrix metalloproteinase-9 contributes to liver fibrosis resolution. Int J Biol Sci. 2018;14(9):1033-40. doi: 10.7150/ijbs.25589
- Faggioli F, Palagano E, Di Tommaso L, et al. B lymphocytes limit senescence-driven fibrosis resolution and favor hepatocarcinogenesis in mouse liver injury. Hepatology. 2018;67(5):1970-85. doi: 10.1002/hep.29636
- Atta HM. Reversibility and heritability of liver fibrosis: Implications for research and therapy. World J Gastroenterol. 2015;21(17):5138-48. doi: 10.3748/wjg.v21.i17.5138
- Jung YK, Yim HJ. Reversal of liver cirrhosis: current evidence and expectations. Korean J Intern Med. 2017;32(2):213-28. doi: 10.3904/kjim.2016.268
- Schuppan D, Ashfaq-Khan M, Yang AT, Kim YO. Liver fibrosis: Direct antifibrotic agents and targeted therapies. Matrix Biol. 2018;68-69:435-51. doi: 10.1016/j.matbio.2018.04.006
- Tacke F. Targeting hepatic macrophages to treat liver diseases. J Hepatol. 2017;66(6):1300-12. doi: 10.1016/j.jhep.2017.02.026
- Tacke F, Weiskirchen R. An update on the recent advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol. 2018;12(11):1143-52. doi: 10.1080/17474124.2018.1530110
- Weiskirchen R, Tacke F. Liver Fibrosis: From Pathogenesis to Novel Therapies. Dig Dis. 2016;34(4):410-22. doi: 10.1159/000444556
- Mridha AR, Wree A, Robertson AAB, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017;66(5):1037-46. doi: 10.1016/j.jhep.2017.01.022
- Omar R, Yang J, Liu H, et al. Hepatic Stellate Cells in Liver Fibrosis and siRNA-Based Therapy. Rev Physiol Biochem Pharmacol. 2016;172:1-37. doi: 10.1007/112_2016_6
- Calvente CJ, Tameda M, Johnson CD, et al. Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223. J Clin Invest. 2019;130:4091-109. doi: 10.1172/JCI122258
- Saijou E, Enomoto Y, Matsuda M, et al. Neutrophils alleviate fibrosis in the CCl4-induced mouse chronic liver injury model. Hepatol Commun. 2018;2(6):703-17. doi: 10.1002/hep4.1178
- Ye D, Zhang T, Lou G, Liu Y. Role of miR-223 in the pathophysiology of liver diseases. Exp Mol Med. 2018;50(9):128. doi: 10.1038/s12276-018-0153-7
- Tsay HC, Yuan Q, Balakrishnan A, et al. Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis. J Hepatol. 2019;70(4):722-34. doi: 10.1016/j.jhep.2018.12.016
- Newsome PN, Fox R, King AL, et al. Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2018;3(1):25-36. doi: 10.1016/S2468-1253(17)30326-6
- Park S, Kim JW, Kim JH, et al. Differential Roles of Angiogenesis in the Induction of Fibrogenesis and the Resolution of Fibrosis in Liver. Biol Pharm Bull. 2015;38(7):980-5. doi: 10.1248/bpb.b15-00325
- Leake I. Liver: Does angiogenesis have a role in the resolution of liver fibrosis? Nat Rev Gastroenterol Hepatol. 2015;12(2):63. doi: 10.1038/nrgastro.2014.230
- Kantari-Mimoun C, Krzywinska E, Castells M, et al. Boosting the hypoxic response in myeloid cells accelerates resolution of fibrosis and regeneration of the liver in mice. Oncotarget. 2017;8(9):15085-100. doi: 10.18632/oncotarget.14749
- Lee HS, Choi J, Son T, et al. Altered AKAP12 expression in portal fibroblasts and liver sinusoids mediates transition from hepatic fibrogenesis to fibrosis resolution. Exp Mol Med. 2018;50(4):48. doi: 10.1038/s12276-018-0074-5
- Chen L, Brenner DA, Kisseleva T. Combatting Fibrosis: Exosome-Based Therapies in the Regression of Liver Fibrosis. Hepatology Commun. 2018;3(2):180-92. doi: 10.1002/hep4.1290
- Poilil Surendran S, George Thomas R, Moon MJ, Jeong YY. Nanoparticles for the treatment of liver fibrosis. Int J Nanomedicine. 2017;12:6997-7006. doi: 10.2147/IJN.S145951
- Bartneck M, Scheyda KM, Warzecha KT, et al. Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases. Biomaterials. 2015;37:367-82. doi: 10.1016/j.biomaterials.2014.10.030
- Caliari SR, Perepelyuk M, Soulas EM, et al. Gradually softening hydrogels for modeling hepatic stellate cell behavior during fibrosis regression. Integr Biol (Camb.). 2016;8(6):720-8. doi: 10.1039/c6ib00027d
- Sumida Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. Hepatology Res. 2019. doi: 10.1111/hepr.13425
- Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016;150(5):1147-59.e5. doi: 10.1053/j.gastro.2016.01.038
- Kumar V, Mahato RI. Delivery and targeting of miRNAs for treating liver fibrosis. Pharmaceutical Res. 2015;32(2):341-61. doi: 10.1007/s11095-014-1497-x